# Genmab A/S

Type: Company (GMAB)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/genmab-as
Canonical HTML page: https://getbiobrief.com/entity/genmab-as

## Recent coverage (2 stories)

### Genmab Navigates Revenue Miss as 2026 Guidance Signals Strategic Pivot
2026-02-19 08:26:16 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Full story: https://getbiobrief.com/story/genmab-q4-2025-earnings-analysis-revenue-miss-2026-guidance

### Biotech Volatility: Genmab Profits Slip as Clinical Trials Drive Market Swings
2026-02-18 07:17:46 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 28

Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
Full story: https://getbiobrief.com/story/genmab-earnings-clinical-trial-volatility

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.